Code No. | D162-4 | Print out |
Anti-Flavocytochrome b558 (Human) mAb-FITC | ||
Price | ¥30,000 | |
Size | 100 µL (500 µg/mL) | |
Availability (in Japan) | 10 or more
(In Japan at 17:00, Mar 28, 2024 in JST) |
|
Clonality | Monoclonal | |
Clone | 7D5 | |
Isotype (Immunized Animal) |
Mouse IgG1 | |
Applications | FCM 10 µg/mL (final concentration) |
|
Immunogen (Antigen) |
Human cytochrome b rich fraction | |
Reactivity [Gene ID] | ||
Storage buffer | 500 µg/mL in PBS/1% BSA/0.09% NaN3 | |
Storage temp. | 4°C | |
Conjugate | FITC | |
Manufacturer | MBL | |
Alternative names | CYBA, CYBB, p22-PHOX, cytochrome b-245 light chain, p22phox, cytochrome b light chain, p22 phagocyte B-cytochrome, cytochrome | |
Background | The NADPH oxidase is a multicomponent enzyme that transfers electrons from NADPH to O2 to generate superoxide (O2-), a key part of the phagocytic or neutrophilic respiratory burst response. Flavocytochrome b558 is the catalytic component of the phagocyte NADPH oxidase. It is a transmembrane heterodimer composed of a large glycoprotein, gp91phox (PHagocyte OXidase) and a smaller protein, p22phox. Upon cell stimulation, flavocytochrome b558 assembles with p67phox, p47phox, and the GTP-binding protein Rac and becomes activated to generate O2-. Mutations in gp91phox, p22phox, or other components of the NADPH oxidase can result in chronic granulomatous disease, which is associated with significant morbidity and mortality due to a predisposition to recurrent bacterial and fungal infections. | |
Related products | D162-3 Anti-Flavocytochrome b558 (Human) mAb D162-5 Anti-Flavocytochrome b558 (Human) mAb-PE |
|
Product category | Research area:Signal transduction Cellular stress | |
Data | ||
Citations | Flow Cytometry
|